Titre : Filamines

Filamines : Questions médicales fréquentes

Termes MeSH sélectionnés :

Attention Deficit and Disruptive Behavior Disorders
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Filamines : Questions médicales les plus fréquentes", "headline": "Filamines : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Filamines : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-02-24", "dateModified": "2025-02-18", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Filamines" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Protéines des microfilaments", "url": "https://questionsmedicales.fr/mesh/D008840", "about": { "@type": "MedicalCondition", "name": "Protéines des microfilaments", "code": { "@type": "MedicalCode", "code": "D008840", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.220.525" } } }, "about": { "@type": "MedicalCondition", "name": "Filamines", "alternateName": "Filamins", "code": { "@type": "MedicalCode", "code": "D064448", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Fumihiko Nakamura", "url": "https://questionsmedicales.fr/author/Fumihiko%20Nakamura", "affiliation": { "@type": "Organization", "name": "School of Pharmaceutical Science and Technology, Life Science Platform , Tianjin University , 92 Weijin Road , Nankai District, Tianjin 300072 , China." } }, { "@type": "Person", "name": "Jean-Philippe Rosa", "url": "https://questionsmedicales.fr/author/Jean-Philippe%20Rosa", "affiliation": { "@type": "Organization", "name": "Hémostase, Inflammation, Thrombose, UMR S1176, INSERM, Université Paris-Sud, Université Paris-Saclay, Le Kremlin Bicêtre, France." } }, { "@type": "Person", "name": "Marijke Bryckaert", "url": "https://questionsmedicales.fr/author/Marijke%20Bryckaert", "affiliation": { "@type": "Organization", "name": "Hémostase, Inflammation, Thrombose, UMR S1176, INSERM, Université Paris-Sud, Université Paris-Saclay, Le Kremlin Bicêtre, France." } }, { "@type": "Person", "name": "Hana Raslova", "url": "https://questionsmedicales.fr/author/Hana%20Raslova", "affiliation": { "@type": "Organization", "name": "Unité Mixte de Recherche (UMR) 1170, INSERM, Equipe Labelllisée Ligue Nationale Contre le Cancer, Gustave Roussy Cancer Campus, Université Paris-Sud, Université Paris-Saclay, Villejuif, France." } }, { "@type": "Person", "name": "Sashidar Bandaru", "url": "https://questionsmedicales.fr/author/Sashidar%20Bandaru", "affiliation": { "@type": "Organization", "name": "Division of Clinical Pathology, Sahlgrenska Academy Hospital, 413 45 Gothenburg, Sweden." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "The Self-Evaluation of Negative Symptoms in Differentiating Deficit Schizophrenia: The Comparison of Sensitivity and Specificity with Other Tools.", "datePublished": "2023-03-06", "url": "https://questionsmedicales.fr/article/36878191", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1159/000529244" } }, { "@type": "ScholarlyArticle", "name": "Rate control deficits during pinch grip and ankle dorsiflexion in early-stage Parkinson's disease.", "datePublished": "2023-03-03", "url": "https://questionsmedicales.fr/article/36867628", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1371/journal.pone.0282203" } }, { "@type": "ScholarlyArticle", "name": "Immersive virtual reality for improving cognitive deficits in children with ADHD: a systematic review and meta-analysis.", "datePublished": "2023-02-18", "url": "https://questionsmedicales.fr/article/36845650", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s10055-023-00768-1" } }, { "@type": "ScholarlyArticle", "name": "Association between olfactory dysfunction and mood disturbances with objective and subjective cognitive deficits in long-COVID.", "datePublished": "2023-02-02", "url": "https://questionsmedicales.fr/article/36818111", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3389/fpsyg.2023.1076743" } }, { "@type": "ScholarlyArticle", "name": "Structural brain signatures of frailty, defined as accumulation of self-reported health deficits in older adults.", "datePublished": "2023-01-19", "url": "https://questionsmedicales.fr/article/36743441", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3389/fnagi.2023.1065191" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Acides aminés, peptides et protéines", "item": "https://questionsmedicales.fr/mesh/D000602" }, { "@type": "ListItem", "position": 3, "name": "Protéines", "item": "https://questionsmedicales.fr/mesh/D011506" }, { "@type": "ListItem", "position": 4, "name": "Protéines du cytosquelette", "item": "https://questionsmedicales.fr/mesh/D003598" }, { "@type": "ListItem", "position": 5, "name": "Protéines des microfilaments", "item": "https://questionsmedicales.fr/mesh/D008840" }, { "@type": "ListItem", "position": 6, "name": "Filamines", "item": "https://questionsmedicales.fr/mesh/D064448" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Filamines - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Filamines", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-17", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Filamines", "description": "Comment diagnostiquer une anomalie des filamines ?\nQuels tests sont utilisés pour évaluer les filamines ?\nLes filamines peuvent-elles être détectées par imagerie ?\nQuels symptômes indiquent un problème de filamines ?\nLes tests sanguins peuvent-ils aider au diagnostic ?", "url": "https://questionsmedicales.fr/mesh/D064448?mesh_terms=Attention+Deficit+and+Disruptive+Behavior+Disorders&page=1000#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Filamines", "description": "Quels sont les symptômes d'une déficience en filamines ?\nLes troubles neurologiques sont-ils liés aux filamines ?\nLes douleurs musculaires sont-elles fréquentes ?\nLes déformations squelettiques sont-elles courantes ?\nLes symptômes varient-ils selon l'âge ?", "url": "https://questionsmedicales.fr/mesh/D064448?mesh_terms=Attention+Deficit+and+Disruptive+Behavior+Disorders&page=1000#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Filamines", "description": "Peut-on prévenir les anomalies des filamines ?\nLe dépistage précoce est-il utile ?\nLes conseils génétiques sont-ils recommandés ?\nL'exercice peut-il aider à prévenir des complications ?\nY a-t-il des recommandations diététiques ?", "url": "https://questionsmedicales.fr/mesh/D064448?mesh_terms=Attention+Deficit+and+Disruptive+Behavior+Disorders&page=1000#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Filamines", "description": "Quels traitements sont disponibles pour les anomalies des filamines ?\nLa physiothérapie est-elle efficace ?\nDes médicaments sont-ils prescrits ?\nLa chirurgie est-elle une option ?\nY a-t-il des traitements expérimentaux ?", "url": "https://questionsmedicales.fr/mesh/D064448?mesh_terms=Attention+Deficit+and+Disruptive+Behavior+Disorders&page=1000#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Filamines", "description": "Quelles complications peuvent survenir avec les anomalies des filamines ?\nLes anomalies des filamines peuvent-elles affecter la respiration ?\nY a-t-il un risque accru de chutes ?\nLes complications sont-elles réversibles ?\nLes complications peuvent-elles affecter la qualité de vie ?", "url": "https://questionsmedicales.fr/mesh/D064448?mesh_terms=Attention+Deficit+and+Disruptive+Behavior+Disorders&page=1000#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Filamines", "description": "Quels sont les facteurs de risque pour les anomalies des filamines ?\nLes hommes et les femmes sont-ils également affectés ?\nL'âge joue-t-il un rôle dans le risque ?\nLes facteurs environnementaux influencent-ils le risque ?\nLes antécédents médicaux augmentent-ils le risque ?", "url": "https://questionsmedicales.fr/mesh/D064448?mesh_terms=Attention+Deficit+and+Disruptive+Behavior+Disorders&page=1000#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une anomalie des filamines ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic se fait par des tests génétiques et des analyses histologiques." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour évaluer les filamines ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests de séquençage génétique et des biopsies musculaires peuvent être utilisés." } }, { "@type": "Question", "name": "Les filamines peuvent-elles être détectées par imagerie ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Non, les filamines ne sont pas visibles par imagerie, mais des anomalies peuvent être observées." } }, { "@type": "Question", "name": "Quels symptômes indiquent un problème de filamines ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Des faiblesses musculaires, des déformations squelettiques et des troubles neurologiques." } }, { "@type": "Question", "name": "Les tests sanguins peuvent-ils aider au diagnostic ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Les tests sanguins ne détectent pas directement les filamines, mais peuvent évaluer la fonction musculaire." } }, { "@type": "Question", "name": "Quels sont les symptômes d'une déficience en filamines ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent faiblesse musculaire, troubles de l'équilibre et déformations." } }, { "@type": "Question", "name": "Les troubles neurologiques sont-ils liés aux filamines ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des troubles neurologiques peuvent survenir en raison d'anomalies des filamines." } }, { "@type": "Question", "name": "Les douleurs musculaires sont-elles fréquentes ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les douleurs musculaires peuvent être un symptôme associé à des anomalies des filamines." } }, { "@type": "Question", "name": "Les déformations squelettiques sont-elles courantes ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des déformations squelettiques peuvent se produire en raison de dysfonction des filamines." } }, { "@type": "Question", "name": "Les symptômes varient-ils selon l'âge ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les symptômes peuvent varier en fonction de l'âge et de la gravité de l'anomalie." } }, { "@type": "Question", "name": "Peut-on prévenir les anomalies des filamines ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Actuellement, il n'existe pas de méthodes de prévention connues pour les anomalies des filamines." } }, { "@type": "Question", "name": "Le dépistage précoce est-il utile ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Le dépistage précoce peut aider à gérer les symptômes, mais ne prévient pas les anomalies." } }, { "@type": "Question", "name": "Les conseils génétiques sont-ils recommandés ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les conseils génétiques peuvent être utiles pour les familles à risque d'anomalies." } }, { "@type": "Question", "name": "L'exercice peut-il aider à prévenir des complications ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "L'exercice régulier peut aider à maintenir la force musculaire et la mobilité." } }, { "@type": "Question", "name": "Y a-t-il des recommandations diététiques ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation équilibrée peut soutenir la santé musculaire, mais ne prévient pas les anomalies." } }, { "@type": "Question", "name": "Quels traitements sont disponibles pour les anomalies des filamines ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements incluent la physiothérapie, la gestion des symptômes et parfois la chirurgie." } }, { "@type": "Question", "name": "La physiothérapie est-elle efficace ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la physiothérapie peut aider à améliorer la force musculaire et la mobilité." } }, { "@type": "Question", "name": "Des médicaments sont-ils prescrits ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Des médicaments peuvent être prescrits pour gérer la douleur et les symptômes associés." } }, { "@type": "Question", "name": "La chirurgie est-elle une option ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "La chirurgie peut être envisagée pour corriger des déformations squelettiques sévères." } }, { "@type": "Question", "name": "Y a-t-il des traitements expérimentaux ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Des traitements expérimentaux sont en cours d'étude, mais leur efficacité n'est pas encore prouvée." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec les anomalies des filamines ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent des troubles de la mobilité, des douleurs chroniques et des déformations." } }, { "@type": "Question", "name": "Les anomalies des filamines peuvent-elles affecter la respiration ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des anomalies sévères peuvent entraîner des problèmes respiratoires en raison de la faiblesse musculaire." } }, { "@type": "Question", "name": "Y a-t-il un risque accru de chutes ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la faiblesse musculaire et les troubles de l'équilibre augmentent le risque de chutes." } }, { "@type": "Question", "name": "Les complications sont-elles réversibles ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être gérées, mais beaucoup ne sont pas réversibles." } }, { "@type": "Question", "name": "Les complications peuvent-elles affecter la qualité de vie ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les complications liées aux anomalies des filamines peuvent significativement affecter la qualité de vie." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque pour les anomalies des filamines ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs de risque incluent des antécédents familiaux et certaines mutations génétiques." } }, { "@type": "Question", "name": "Les hommes et les femmes sont-ils également affectés ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Les anomalies des filamines peuvent affecter les deux sexes, mais certaines conditions sont plus fréquentes chez les hommes." } }, { "@type": "Question", "name": "L'âge joue-t-il un rôle dans le risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines anomalies peuvent se manifester plus tôt ou plus tard selon l'âge." } }, { "@type": "Question", "name": "Les facteurs environnementaux influencent-ils le risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Actuellement, il n'y a pas de preuves solides que les facteurs environnementaux influencent le risque." } }, { "@type": "Question", "name": "Les antécédents médicaux augmentent-ils le risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents médicaux de troubles musculaires peuvent augmenter le risque d'anomalies." } } ] } ] }

Sources (10000 au total)

The Self-Evaluation of Negative Symptoms in Differentiating Deficit Schizophrenia: The Comparison of Sensitivity and Specificity with Other Tools.

Psychometric properties of the Self-evaluation of Negative Symptoms (SNS) in subjects with the deficit subtype of schizophrenia (SCZ-D) have not been investigated so far. This study had the following ... Participants were 82 stable outpatients with schizophrenia, including 40 individuals with SCZ-D and 42 individuals with the non-deficit subtype (SCZ-ND).... Internal consistency was acceptable-to-good in both groups. Factor analysis revealed two dimensions (apathy and emotional). There were significant positive correlations of the SNS total score with the... The present findings indicate that the SNS has good psychometric properties in subjects with SCZ-D and those with SCZ-ND. Moreover, the SNS, the PANSS, and the SOFAS might be used as screening tools f...

Rate control deficits during pinch grip and ankle dorsiflexion in early-stage Parkinson's disease.

Much of our understanding of the deficits in force control in Parkinson's disease (PD) relies on findings in the upper extremity. Currently, there is a paucity of data pertaining to the effect of PD o... The purpose of this study was to concurrently evaluate upper- and lower-limb force control in early-stage PD and a group of age- and gender-matched healthy controls.... Twenty individuals with PD and twenty-one healthy older adults participated in this study. Participants performed two visually guided, submaximal (15% of maximum voluntary contractions) isometric forc... Compared with controls, PD demonstrated slower rates of force development and force relaxation during the foot task, and a slower rate of relaxation during the hand task. Force variability was similar... Together, these results provide quantitative evidence of an impaired capacity in PD to produce submaximal and rapid force across multiple effectors. Moreover, results suggest that force control defici...

Association between olfactory dysfunction and mood disturbances with objective and subjective cognitive deficits in long-COVID.

The coronavirus disease 2019 (COVID-19) has been associated with olfactory dysfunction. The persistent symptoms of anosmia or hyposmia were associated in previous studies with the development of memor... One hundred twenty-eight long-COVID participants were recruited. Reported symptomatology, subjective memory complaints, anxiety and depression symptomatology, and trait-anxiety were assessed. Subjecti... The subjective memory complaints and the anxiety and depression symptoms were similar among the groups, but the score in general cognitive function was lower in the participants with symptoms of acute... Olfactory dysfunction in the acute phase of the infection by COVID-19 is related to cognitive deficits in objective tests, and mood disturbances are associated with self-reported and objective memory....

Structural brain signatures of frailty, defined as accumulation of self-reported health deficits in older adults.

Frailty in older adults has been associated with reduced brain health. However, structural brain signatures of frailty remain understudied. Our aims were: (1) Explore associations between a frailty in... We designed a cross-sectional observational study from a population-based study (The Irish Longitudinal Study on Aging: TILDA). Participants aged ≥50 years who underwent the wave 3 MRI sub-study were ... In 523 participants (mean age 69, 49% men), lower cortex and thalamic volumes were independently associated with higher FI. Sensory and functional difficulties, diabetes, polypharmacy, knee pain, and ... The FI used had a recognizable but subtle structural brain signature in this sample. Only some FI deficits were directly associated with cortex volume, suggesting scope for developing FIs that include...

P50 sensory gating, cognitive deficits and depressive symptoms in first-episode antipsychotics-naïve schizophrenia.

Sensory gating P50 (SG-P50) may be involved in the pathophysiological mechanisms of impaired cognition in schizophrenia (SCZ). Comorbid depressive symptoms are common in SCZ patients and are also foun... We recruited 103 FEAN-SCZ patients (depression: n = 63; non-depression: n = 40) and 55 healthy controls. SG-P50 was measured using the standard auditory dual-click (S1&S2) paradigm. Clinical symptoms ... Compared with non-depressive patients, depressive patients had a significantly larger S2 amplitude (p = 0.005) and a higher S2/S1 ratio at trend level (p = 0.075) after corrected. There were significa... SG-P50 deficit may be an informational biomarker for depressive symptoms and neurocognitive impairments in FEAN-SCZ patients....

Association of cholesterol level with dopamine loss and motor deficits in Parkinson disease: A cross-sectional study.

Cholesterol is vital in neuronal function; however, the influence of cholesterol levels on parkinsonism is unclear. This study investigated the relationship between baseline total cholesterol (TC) lev... This cross-sectional study enrolled 447 drug-naïve patients with PD who underwent dopamine transporter (DAT) imaging. Multivariate linear regression was used to investigate the effect of cholesterol l... No significant correlation was found between TC levels and DAT availability after adjusting for potential confounders. Multivariate linear regression showed that TC levels were significantly and negat... This study suggests that TC levels affect parkinsonian motor symptoms, especially in subjects with low cholesterol status, whereas the severity of axial motor symptoms is negatively associated with TC...

Assessment of Bioenergetic Deficits in Patients With Parkinson Disease and Progressive Supranuclear Palsy Using 31P-MRSI.

Bioenergetic disturbance, mainly caused by mitochondrial dysfunction, is an established pathophysiological phenomenon in neurodegenerative movement disorders. The... In total, 30 PwPD, 16 PwPSP, and 25 healthy control subjects (HCs) underwent a clinical examination, structural magnetic resonance imaging, and... High-energy phosphate metabolites were remarkably decreased in PwPD, particularly in the basal ganglia (-42% compared with healthy controls and -43% compared with PwPSP, p<.0001). This result was not ... Our study shows that mitochondrial dysfunction and bioenergetic depletion contribute to idiopathic Parkinson's disease pathophysiology but not to progressive supranuclear palsy. Combined morphometric ...